Effect of CB-154 therapy on the glucose tolerance, IRI and GH response to glucose administration in acromegaly.

Publisher Website
Google Scholar
Abstract
Effects of CB-154 [bromocryptine] therapy on glucose tolerance, IRI [immunoreactive insulin] and GH [growth hormone] responses to oral glucose administration in 5 acromegalic patients with impaired glucose tolerance were examined. Glucose tolerance improved in all patients with a reduction in GH levels. Insulin secretion in response to the oral glucose administration was exaggerated in 3 patients, while it was suppressed in 2 patients who had severely impaired glucose tolerance. After receiving CB-154 therapy, hyperresponsiveness of insulin observed in the 3 patients and a suppressed response in 1 patient were corrected to normal, while a low response in another stayed unchanged. This observation suggests that variable abnormalities in insulin secretion induced by excess GH improve with a decrease in plasma GH levels. Abnormal GH secretion in response to hyperglycemia persisted after CB-154 administration in spite of decreased basal plasma GH levels.